Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Kidney Cancer Research Bureau

Status and phase: Completed; Phase 2

Conditions: Metastatic Renal Cell Carcinoma

Treatments: Drug: Capecitabine

Study type: Interventional

Funder types: Other

Identifiers

NCT01182142

CRT-06.CAP

Details and patient eligibility

About

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.

Enrollment: 51 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed non-clear cell renal cell carcinoma
• confirmed metastatic sites
• no chemotherapy in history

Exclusion criteria

• metastases in CNS
• previous targeted therapy
• other tumor

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

51 participants in 1 patient group

Capecitabine

Experimental group

Description:

All patients will receive capecitabine.

Treatment:

Drug: Capecitabine